Expression and Potential Biomarkers of Regulators for M7G RNA Modification in Gliomas
Open Access
- 9 May 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 886246
Abstract
Gliomas are the most frequent primary malignant brain tumors of the central nervous system, causing significant impairment and death. There is mounting evidence that N7 methylguanosine (m7G) RNA dysmethylation plays a significant role in the development and progression of cancer. However, the expression patterns and function of the m7G RNA methylation regulator in gliomas are yet unknown. The goal of this study was to examine the expression patterns of 31 critical regulators linked with m7G RNA methylation and their prognostic significance in gliomas. To begin, we systematically analyzed patient clinical and prognostic data and mRNA gene expression data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. We found that 17 key regulators of m7G RNA methylation showed significantly higher expression levels in gliomas. We then divided the sample into two subgroups by consensus clustering. Cluster 2 had a poorer prognosis than cluster 1 and was associated with a higher histological grade. In addition, cluster 2 was significantly enriched for cancer-related pathways. Based on this discovery, we developed a risk model involving three m7G methylation regulators. Patients were divided into high-risk and low-risk groups based on risk scores. Overall survival (OS) was significantly lower in the high-risk group than in the low-risk group. Further analysis showed that the risk score was an independent prognostic factor for gliomas.Keywords
This publication has 48 references indexed in Scilit:
- Genetic and functional analyses implicate the NUDT11 , HNF1B , and SLC22A3 genes in prostate cancer pathogenesisProceedings of the National Academy of Sciences, 2012
- Understanding the contribution of synonymous mutations to human diseaseNature Reviews Genetics, 2011
- Myc Regulation of mRNA Cap MethylationGenes & Cancer, 2010
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- CYFIP2, a Direct p53 Target, is Leptomycin-B SensitiveCell Cycle, 2007
- Epidemiology and molecular pathology of gliomaNature Clinical Practice Neurology, 2006
- Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomesGenome Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2PProceedings of the National Academy of Sciences, 2001
- Increased apoptosis induction by 121F mutant p53The EMBO Journal, 1999